Analysguiden: Accelerated Development of RP501 for Dry Eyes
In October, Redwood Pharma announced a strategic change in the form of accelerated development of RP501 for dry eyes. RP501 can reach the market within two years and thus generate revenue in the near future. Analysguiden adjusts its target price to SEK 10.RP501 Can Reach the Market Within 2 yearsAs expected, Redwood Pharma reported no revenue during H1 2021. Operating profit amounted to SEK -11 million (-8) and the company’s cash position amounted to SEK 22 million at the end of the period. In October, a strategic change was announced in the form of accelerated development of RP501 for